As a further significant development for ddRNAi technology, our licensee Calimmune treated their first patient in a Phase I/II trial of its HIV/AIDS therapeutic candidate, Cal 1, in July. Calimmune’s Chief Scientist, Dr Geoff Symonds, will give a brief overview of this program at our Sydney---based shareholder meeting tomorrow. His presentation will be lodged with ASX and posted on the Company’s website.
